Priscille Poitrinal

Priscille Poitrinal, MD has a strong and extensive background in market access and pricing within the pharmaceutical industry. Priscille has held various strategic roles throughout their career. From 1999 to 2006, they worked as a Health Outcomes-Pricing & Reimbursement Access Manager at Eli Lilly and Company. Following that, they joined AMGEN (EUROPE) GmbH as the Director International Health Economics & Reimbursement-Oncology Franchise Head from 2006 to 2011. Afterwards, they served as the Market Access Head Europe and Emerging Markets at Human Genome Sciences from 2011 to 2012. Priscille then worked as an Independent Consultant at Market Access Consulting, offering their expertise in market access, health economics, health technology assessment, and reimbursement to pharma/biotech organizations from 2013 to 2013. Priscille subsequently joined Ferring Pharmaceuticals as the Global Market Access & Pricing Head from 2013 to 2017. Currently, Priscille is the VP, Head of Market Access & Pricing Europe at Ultragenyx Pharmaceutical Inc. since 2017.

Priscille Poitrinal, MD pursued their education in a chronological order. Priscille initially attended Université de Poitiers from 1984 to 1991, where they earned a degree in Medicine, specifically a MD. Following this, from 1991 to 1996, they attended Université de Reims Champagne-Ardenne and obtained a degree in Medical Speciality, with a focus on Public Health. Additionally, they pursued a Master of Science degree in Health Economics & Health System Management from Université Paris-Sorbonne in 1995. Lastly, in 1994, they attended Université Paris-Sud and earned a License in Biostatistics & Epidemiology.